egle - Modulating Treg Cells to Balance Immunity
Time 2022-09-08 12:02:41Web Name: egle - Modulating Treg Cells to Balance Immunity
WebSite: http://www.egle-tx.com
ID:308122
Keywords:
Treg,Modulating,egle,CellsDescription:
Modulating Treg Cells to Balance Immunity
Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.
About Us
According to Greek poet Hesiod, Aglaea (Egle) was the youngest of the Zeus Daughters Charites, symbolizing beauty, splendor, glory, and magnificence, all essential attributes to enlighten hope for patients suffering from severe diseases and to deploy unprecedent remarkable science to meet the unmet.
Inspired by the myth of Aglaea, Egle Therapeutics has been built with the sole driver of assembling the most notable scientific expertise with genuine talents to bring well-being to the patient’s community.
Who we Are
Established in early 2020, as a spin-out of Institut Curie by Luc Boblet, serial biotech entrepreneur, and Dr Eliane Piaggio PhD, Director of the Translational Immunotherapy Team at Institut Curie, Egle Therapeutics is developing first-in-class immunotherapies targeting suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases.
Our Science
Egle’s scientific foundations benefits from decades of breakthrough academic research leading to unprecedented computational based IL-2 modified variants and a unique translational-based target discovery platform unveiling novel therapeutic Treg targets.
The key element of Egle’s core approach leverages of unifying therapeutic potentials of antibody specific targeting combined with the selective mechanism of action of modified cytokine for arming or disarming the most immunosuppressive Tregs to restore the immune response.
Egle deploys its first-in-class technology platforms to building a furnished drug pipeline of novel immunotherapies against Tregs with tremendous potential in the oncology and auto-immunity fields.
Leadership
Luc Boblet
Co-Founder and Chief Executive Officer
15+ industrial experience in therapeutics R&D, corporate business development and start-up entrepreneurship including exit. Former EVP Business Dvp at HIFIBIO, Co-founder and CEO H-IMMUNE (acquired by HIFIBIO), Co-founder and CEO Pathoquest Former Board member at the BioAster Technological Research Institute. MSc in biotech engineering, MSc in Virology Paris VII University, trained as a PhD in Immuno Virology Paris VII University.Eliane Piaggio Ph.D
Scientific founder & Scientific Advisor
20+ experience in academic and translationnal research in immunology. INSERM Research Director U932 Immunity and cancer, Head of Transimm Team (Translationnal Immunoterapy) at Institut Curie. Multiple ongoing research collaborations with top tiers pharma (Genentech, Novartis, Sanofi, Transgene). Former Professor of Immunology at University National University of Rosario.Stéphane Postic
Chief Financial Officer
15+ experience in finance management both in large international retail organizations and biotech companies including IPO. Currently part-time CFO at DaVolterra Former part time CFO at H-IMMUNE (acquired by HIFIBIO), part time CFO at Pathoquest and full time CFO of Genfit, in charge of financials including IPO on Euronext. Msc in Finance Management from EM Lyon.Board Members
Pierre Legault
Chairman of the Board
Pierre Legault, MBA, CA, CPA, serves as chairman and a member of our Board of Egle Therapeutics since March 2022, as chairman and a member of the Board of Bicycle since March 2019. Mr. Legault, serves as chairman of the Board of Amolyt Pharma SA since December 2020, has been chairman of the board of Artios Pharma Limited since February 2018, has been chairman of the Board of Sitryx Therapeutics Limited since March of 2021, has served on the board of directors of Poxel SA since January 2016 and has been chairman of such board since March 2016, has served on the board of directors of Urovant Sciences Limited as a director since July 2018 and has served as a director of Syndax Pharmaceuticals since January 2017. Mr. Legault has also previously served as a member of the boards of directors at Clementia Pharmaceuticals, Forest Laboratories, Tobira Therapeutics, NPS Pharmaceuticals, Regado Biosciences, ARMO Biosciences, Iroko Pharmaceuticals, Cyclacel Pharmaceuticals, Eckerd Pharmacy and NephroGenex where he also served as the Chairman and Chief Executive Officer from 2012 to 2016. From 2010 to 2012, Mr. Legault served as the Chief Executive Officer of Prosidion Ltd., a subsidiary of Astellas Pharma Inc., and from 2009 to 2010, he served as the Chief Financial Officer and Treasurer of OSI Pharmaceuticals, Inc. Mr. Legault also previously served as the Chief Executive Officer of Eckerd Pharmacy and Chief Administrative Officer of the Rite Aid Corporation. Between 1989 and 2005, Mr. Legault held various global roles such as President, Chief Executive Officer and Chief Financial Officer at legacy companies of the Sanofi-Aventis group. Mr. Legault earned a B.B.A. in Business & International Finance from HEC Montreal, an MBA. in Marketing from McGill University and holds C.A., C.P.A. diplomas. He also studied at Harvard Business School in their Graduate Executive MBA program.
Felice Verduyn - van Weegen
Partner at LSP
Felice Verduyn-van Weegen is a Partner at LSP and has joined the company early 2015. In addition to Egle therapeutics, Felice serves on the Boards of a.o. Vico therapeutics, Amolyt pharma, Evommune and AM-pharma. Prior to joining LSP, Felice was a consultant at McKinsey & Company with a primary focus on healthcare projects. Before McKinsey, she was a neuroscientist and statistical geneticist, working with the prestigious complex traits genetics group at the Broad Institute and Harvard Medical School in Cambridge, USA. Felice was awarded a Bachelor’s degree in Biological Psychology and a Master’s degree in Neuroscience from the VU University, Amsterdam. In addition, she was awarded an MBA degree from Columbia Business School, New York USA.
Vincent Brichard
Venture Partner at LSP
Vincent Brichard is Venture Partner at LSP. He was formerly Senior Vice President and member of the Executive Team of GlaxoSmithKline (GSK) and headed the Business Unit for Immunotherapeutics. He is member of scientific advisory boards and supervisory boards of several European life sciences companies active in the fields of immuno-oncology, vaccines and diagnostics. He authored more than a 100 research manuscripts in leading international journals. He studied medicine at the Louvain University in Brussels and Institute Curie in Paris, received his Ph.D. in tumor immunology at the Ludwig Institute for Cancer Research in Brussels and had the position of a Professor of Oncology at Louvain University, Brussels. He also holds an executive MBA from Harvard Business School.
Sacha Mann
Senior Partner at Takeda Ventures
Sacha Mann joined Takeda Ventures, Inc. (TVI) in June 2021, as Senior Partner, and is based in Vancouver, British Columbia. She has a decade of experience in venture investing and complimentary skills in company creation, management as biotech CEO, business development, and R&D. She has been an advisor and director for various life science companies, incubators / accelerators, and venture capital funds. Previously she was the CEO of Biosys, a venture-backed clinical stage microbiome company, and led several healthcare investments at Inventages. Prior to Inventages, Sacha was an early stage investor focused on innovation and investment at Archangels and BDC Capital. Sacha holds a BSc Honours in Chemistry from the University of British Columbia, a MSc in Biotechnology from Johns Hopkins University and a MBA from Simon Fraser University.
Jean-François Morin
Investment Director at BPI-Innobio2
Jean-François Morin is an Investment Director covering venture capital investments in biotech and medical devices companies. Jean-François currently serves on the Boards of ONA Therapeutics, Sensorion and Orphalan. Prior to joining Bpifrance, he was a Financial Manager at CDC Entreprises, a Funds Management company where he was involved in structuring several investment funds and for the portfolio monitoring, mostly in Venture Capital. He is graduate from EDHEC Business School in France.
Eliane Piaggio
Founder’s representative
Luc Boblet
CEO
Board Observers
Philippe Monteyne
Partner at Fund+
Dr. Philippe Monteyne MD, PhD is a Partner at the VC Fund+ in Belgium. Fund+ is an open ended Fund for long term equity investments in innovative life sciences companies with a focus on Belgium and other European Hubs. The fund wants to create sustainable shareholders’ value, contribute to the development of a leadership position of the Life Sciences sector and generate a tangible, beneficial societal impact. Dr. Monteyne has held senior positions in SmithKline Beecham, GSK, and Sanofi. He served as the Head of Global Vaccine Development at GSK for several years, and then served as Senior VP-Head of Development and CMO at GSK Rare Diseases from 2010 to 2012.Amongst his achievements, was the development and launch of GSK's Cervical Cancer Vaccine, Cervarix, the R&D work that allowed to develop Strimvelis and Tegsedi (gene therapy and oligonucleotide in rare diseases). More recently, he served as Vice President R&D France at Sanofi until early 2015. During that period, he was also Board Member of SARD (Sanofi Aventis R&D), of the LEEM (Pharmaceutical association in France "Les Entreprises du Médicament"), of the Bioaster Insitute in Lyon, and of the « Fondation Plan Alzheimer France ». He is a Board Director of several Biotech companies, in Belgium, France and Spain. Dr. Monteyne was also visiting Professor of Neurology at the UCL (Université Catholique de Louvain), Brussels. He holds an M.D. degree and Ph.D. in Viral Immunology, both at the UCL, is a fully trained Neurologist, and has also been trained in Neuro-Immunology at Pasteur Institute in Paris.
Jacques Mizrahi
Venture Partner at Bioqube
Jacques Mizrahi is Venture Partner at Bioqube Ventures. Jacques has been trained in France (Pitié-Salpetriere, University Paris VI) and in Canada (Sherbrooke University; University of Science; Medical School) in Physiology-Pharmacology, completed by post-doctoral studies at Inserm U36/Hospital Broussais) with Prof. Pierre Corvol. He then started his career in Big Pharma; Glaxo (Paris-France), Eli Lilly (Indianapolis-USA) and Roche (Basel-Switzerland) where he spent over 18 years in R&D in Cardiovascular & Metabolic diseases as Global Therapy area Director as well as leading the Clinical Research & Exploratory Medicine group, bridging Research and clinical development up to PoC). As Global Therapy Area Head, he was a member of the Research & Development Committee in Basel. After leaving Roche, Jacques has oriented his interests towards the development of Biotechs programs via the partnerships with VCs (Aravis); boards of directors of several European Biotechs and Public institutions (Inserm Transfer, IHU Paris).
Elisa El Nouchi
Associate at BPI-Innobio2
Elisa El Nouchi is an Associate in the Life Sciences Investment team at Bpifrance. She currently serves on the Board of AlgoTherapeutix and has participated in multiple investments/refinancing through Bpifrance Funds. Prior to joining Bpifrance, she started her career in the M&A Department of a Specialty Pharmaceutical Company in Paris. She holds a PharmD from the Faculty of Pharmacy Paris-Saclay and a Master in Management from the ESSEC Business School.
Investors
Partners
News
May 5 2022Egle Therapeutics appoints Pierre Legault as Chairman and Board Member.
Learn MorePARIS, France May 5, 2022
Egle Therapeutics appoints Pierre Legault as Chairman and Board Member
Paris, France, 5th May 2022 / Egle Therapeutics SAS (Egle), an emerging biotechnology company dedicated to developing novel immunotherapies for oncology and autoimmune diseases, is pleased to announce Pierre Legault as Chairman and board member as of March 2022. With extensive experience over 35 years in leadership roles at leading companies across the biotech and pharmaceutical sector, Mr. Legault will be a key part of the team as Egle deploys its first-in-class technology platforms to construct a drug pipeline of novel immunotherapies targeting suppressor regulatory T cells (Tregs).
“We’re delighted to welcome Pierre Legault as Chairman and board member of Egle. His depth and breadth of experience will be of great value to us in accelerating Egle’s strategic path forward,” commented entrepreneur Luc Boblet, Co-Founder and CEO of Egle. “Mr. Legault’s professional portfolio will complement our dynamic team as we progress Egle’s mission as a game changer in the field of modulating regulatory T-cells to treat cancer and autoimmune diseases.”
Mr. Pierre Legault, Chairman of the Board of Directors at Egle said, “Egle’s innovative technology platform is an exciting prospect in the field of immunotherapy. I look forward to working with the team to construct a drug pipeline that is committed to improving the health of patients.”
Over the past 5 years, Mr. Legault has been at the cutting-edge of innovative oncology therapeutics, serving as Director of Syndax Pharmaceuticals, and Chairman of the Board at Artios Pharma, Bicycle Therapeutics, and Sitryx Therapeutics. This first-hand experience of wide-ranging novel approaches to treat cancer and autoimmune conditions places Mr. Legault in a very strong position as he joins the team at Egle Therapeutics.
In his early career, Mr. Legault held global roles including President, CEO and CFO at legacy companies of the Sanofi-Aventis group. Over the past decades, Mr. Legault has continued to build a rich profile of experience, holding C-suite executive roles and serving as a board member at over 20 pharmaceutical and biotechnology companies such as Prosidion Ltd., NPS, Armo, Clementia, Poxel, Amolyt Pharma, Urovant Sciences and others.
ENDS
For further information, please contact:
Corporate contact:
Luc Boblet, CEO
Egle Therapeutics
E: contact@egle-tx.com
Media Contact:
Dani Edmunds / Darya Shulakova / Deborah Cockerill
Sciad Communications Ltd
T: +44 (0)20 3405 7892
E: PressTeam@sciad.com
Notes to Editors
About Egle Therapeutics SAS (Egle)
Established in early 2020 as a spin-out of Institut Curie by Luc Boblet, serial biotech entrepreneur, and Dr Eliane Piaggio, PhD, renowned immunologist in the Treg / IL-2 field (INSERM Research Director, Head of the Translational Immunotherapy Team – TransImm – at Institut Curie), Egle Therapeutics develops First-In-Class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The key element of Egle’s core approach is the leveraging of its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. Find out more at www.egle-tx.com.
Oct 22 2021Egle Therapeutics raises 40 million € Series A to develop First-In-Class T-regulatory cells therapies based on Treg-starvers.
Learn MorePARIS, France October 22, 2021
Egle Therapeutics raises 40 million € Series A
to develop First-In-Class T-regulatory cells therapies based on Treg-starvers
LSP and Bpifrance, through its InnoBio 2 Fund, co-led international investor syndicate
Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In- Class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, today announces that it has completed a €40M ($46.4M) Series A financing. The Series A was co-led by LSP and Bpifrance through their InnoBio 2 fund. Fund+, Bioqube Ventures and Takeda Ventures, Inc. also participated in this round.
Egle Therapeutics was founded in early 2020 with a vision to become a game changer in the field of Tregs immunomodulation through the unique concept of Tregs starving and specifically targeting the most immunosuppressive ones. Spun out of Institut Curie, Egle’s scientific foundation leverages unprecedented, computational-based, IL-2 modified variants and newly tumor-associated Treg targets to build a furnished pipeline of First-In-Class immunocytokines against Tregs. The new capital will be used primarily to advance 2 leads assets into the clinic and further strengthen its internal drug pipeline.
“Closing a substantial Series A of €40M from a high-quality syndicate of renowned investors, as well as a partnership with a top big pharma like the one we have announced with Takeda in June 2020, all in less than 18 months, puts Egle on a trajectory to execute its vision of tackling regulatory T cells to restore immunity in patients suffering from cancer and autoimmune diseases” commented Luc Boblet, co-founder and CEO of Egle. “The funding will give us appropriate resources to push the first Treg starvers into the clinic and we feel very privileged to undertake such responsibility for the benefit of the whole patient community”.
The investor syndicate will join the Egle Therapeutics Board which will consist of Felice Verduyn-van Weegen (LSP), Vincent Brichard (LSP), Jean-Francois Morin (Bpifrance – InnoBio 2) and Sacha Mann (Takeda Ventures). Philippe Monteyne (Fund+), Jacques Mizrahi (Bioqube Ventures) and Elisa El Nouchi (Bpifrance InnoBio 2) will join as observers.
“Egle represents a strategic investment in a First-In-Class technology platform based on innovative research with novel T regulatory modulations and potential in the oncology and auto-immunity fields”, commented Vincent Brichard, Venture Partner at LSP. “We feel privileged to be part of such an exciting company, with world class science and look forward to build it out together with the team” adds Felice Verduyn-van Weegen, partner at LSP.
“InnoBio 2 strives to invest in breakthrough ideas and to promote First-In-Class drugs candidates. We are delighted to have co-led a financing round that will enable Egle Therapeutics to broadly invest in its platform technologies, development programs, people and ultimately, towards delivering a pioneering new generation of immunotherapies to patients in need,” said Jean-François Morin, Investment Director at Bpifrance.
About Egle Therapeutics
Established in early 2020, as a spin-out of Institut Curie by Luc Boblet, serial biotech entrepreneur and Dr Eliane Piaggio, PhD, renowned immunologist in the Treg / IL-2 field (INSERM Research Director, Head of the Translational Immunotherapy Team – TransImm – at Institut Curie), Egle Therapeutics develops First-In-Class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The key element of Egle’s core approach is the leveraging of its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. www.egle-tx.com
Contact
Luc Boblet
Chief Executive Officer
Email: lboblet@egle-tx.com
About LSP
LSP is one of the largest European investment firms providing financing for life sciences and health care companies. LSP’s management has raised over €2.7 billion ($3.2 billion) and supported the growth of 300 companies since it started to invest in 1988, including signature deals such as Argenx, Crucell and Neuravi. With offices in Amsterdam, Munich and Boston, LSP currently has the possibility to invest through five strategies, each having a distinctive investment scope and a dedicated team: LSP 6 invests in private early- to late-stage drug development and medical technology companies; LSP HEF 2 focuses on private late-stage medical technology companies; the LSP Dementia Fund invests in companies targeting neurodegenerative diseases; LSP Public targets public healthcare companies; and EBAC is the first healthcare SPAC to exclusively focus on European biotech. LSP is an active contributor to the global life sciences industry and the European life science eco-system by assuming for-profit and not-for-profit roles as initiators, founders and board members in various private and public bodies and organizations, for example being founder and board member of the Oncode Institute. lspvc.com.
About Bpifrance – InnoBio 2
Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export).
InnoBio 2 is an investment fund dedicated to life sciences, managed by Bpifrance, which is also one of the LPs alongside Sanofi, Boehringer Ingelheim, Takeda, Ipsen, Servier, BMS and Pasteur Mutualité. InnoBio 2, aims to invest in companies developing innovative products and services, close to or in early clinical development, with the objective of bringing them until the clinical proof of concept. InnoBio 2 takes minority equity stake in companies and can lead or co-lead the investment rounds. www.bpifrance.com
About Takeda Ventures Inc.
Takeda Ventures, Inc. (TVI) is the corporate venture capital group of Takeda Pharmaceutical Company Limited and was founded in 2001 with the vision of generating disruptive technologies and therapeutic solutions for patients through venture-based partnerships. Their mission is to create strategic growth opportunities for Takeda by building, managing and investing in innovation-based companies.TVI partners with academic innovators, entrepreneurs and venture investors to create and nurture a portfolio of companies in an array of therapeutic areas, including oncology, gastroenterology, neuroscience and rare diseases. For more information visitwww.takedaventures.com
About Fund+
Fund+ is an open-ended Fund for long term equity investment in innovative Life Sciences companies with a focus on Belgiumand other European Biotech Hubs. We want to create sustainable shareholders value, contribute to the development of a leadership position in the Life Sciences sector and generate a tangible, beneficial societal impact.Fund+ has currently 16 innovative portfolio companies active in different therapeutic areas. https://fundplus.be
About Bioqube Ventures
Bioqube Ventures a specialist life sciences investment firm founded in 2016. The team consist out of investment professionals, sector experts and serial entrepreneurs that have a proven track record in successfully building and leading companies on their growth paths. In 2020, Bioqube Ventures launched the Bioqube Factory Fund I with a clear focus on the discovery and development of new therapeutic platforms and assets. With a diversified investment strategy, including a venture creation model and industry guidance through selected strategic partnerships, Bioqube Ventures willexclusively invest in the most promising innovative sciencein Europe. Bioqube Factory Fund I is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (“EFSI”) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing. www.bioqubeventures.com
About Institut Curie
Institut Curie, France’s leading cancer center, combines an internationally-renowned research center with a cutting-edge hospital group that treats all types of cancer, including the rarest. Founded in 1909 by Marie Curie, Institut Curie employs more than 3,700 researchers, physicians, and health professionals across three sites (Paris, Saint-Cloud, and Orsay), working on its three missions: treatment, research, and teaching. A private foundation with public utility status, Institut Curie is authorized to receive donations and legacies, and thanks to the support of its donors, is able to make discoveries more quickly, improving treatments and quality of life for patients. www.curie.fr
Nov 26 2020 Egle Therapeutics Identifies First Novel Regulatory T-cell Targets in Research Alliance with Takeda.
Egle to receive R&D milestone payment and equity funding from Takeda.
PARIS, France November 26th, 2020
Egle Therapeutics Identifies First Novel Regulatory T-cell Targets in Research Alliance with Takeda
Egle to receive R&D milestone payment and equity funding from Takeda
Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing first-in class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, today announces that it has achieved the first milestone in its strategic research alliance with Takeda Pharmaceutical Company Limited (“Takeda”).In the course of the strategic research alliance that was announced in June 2020, Egle will validate novel tumor-infiltrating regulatory T-cell (Treg) targets against which Takeda will develop potential therapies.
Egle has leveraged its unique bioinformatic and translational capabilities to successfully identify targets that will now be pursued under the terms of the alliance. Upon achievement of the target identification, Egle will receive an R&D milestone payment and investment from Takeda.
Luc Boblet, CEO of Egle, commented “Reaching this first technical milestone marks our positive progress towards our joint goal with Takeda, of creating the next generation of differentiated immunotherapies against Tregs, and provides strong validation of the work being done at Egle. We look forward to continuing our productive alliance with Takeda while pushing further our internal programs through the equity component of the alliance.”
“We have made great progress in our collaboration with Egle and are thrilled with the speed of which we identified our first novel Treg targets,” said Loïc Vincent, Head, Oncology Drug Discovery Unit at Takeda. “We hope to build upon this momentum in the next phase of our partnership to enable and ultimately deliver new immuno-oncology therapeutic options.”
About Egle Therapeutics
Established in early 2020, as a spin-out of Institut Curie by Luc Boblet, serial biotech entrepreneur (former co-founder and CEO of PathoQuest, and former co-founder and CEO of H-Immune sold to HifiBio Therapeutics) and Dr Eliane Piaggio, PhD, renowned immunologist in the Treg / IL-2 field (INSERM Research Director, Head of the Translational Immunotherapy Team – TransImm – at Institut Curie), Egle Therapeutics is developing first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases.
The key element of Egle’s core approach is the leveraging of its translational-based target discovery engine to unveil novel therapeutic Treg targets and vectorize computationally designed resurfaced cytokines acting as antagonists or as selective Treg-agonists. Egle’s flagship program pioneers dis-engagement of tumor-infiltrating Tregs through a proprietary series of IL-2 variants featuring a unique antagonism mechanism of action.
To find out more about Egle Therapeutics, please visit www.egle-tx.com
Contact
Luc Boblet
Chief Executive Officer
Email: lboblet@egle-tx.com
Egle Therapeutics enters into a corporate strategic research alliance with Takeda to uncover novel tumor-specific regulatory T-cell targets and develop unique anti-suppressor-based immunotherapies.
Learn MorePARIS, France June 11, 2020
Egle Therapeutics enters into a corporate strategic research alliance with Takeda to uncover novel tumor-specific regulatory T-cell targets and develop unique anti-suppressor-based immunotherapies
Egle Therapeutics SAS, an emerging biotechnology company focused on developing first-in-class immunotherapies targeting immune suppressor regulatory T-cells for oncology and autoimmune diseases, announced today a corporate strategic research alliance with Takeda Pharmaceutical Company Limited (“Takeda”) with the goal of validating novel tumor-infiltrating regulatory T-cell (Treg) targets against which Takeda will develop potential therapies.
As a newly established bioscience company spun out of Institut Curie in the field of Treg immune modulation, Egle Therapeutics has assembled a proprietary translational based target discovery engine leveraging patient samples to map out - at the single cell level - unique transcriptomic signatures and targets specific for tumor-infiltrating Treg sub-populations. Capitalizing on these newly identified tumor-infiltrating Treg targets, the company is building a proprietary Treg modulating drug pipeline which also includes computationally designed resurfaced IL-2 proprietary variants, featuring unique mechanism of action to engage or dis-engage Tregs.
Under the terms of the agreement, Egle Therapeutics will lead target validation efforts on a subset targets Egle has identified and Takeda will be responsible for the development, manufacturing, and commercialization of resulting therapies. Egle Therapeutics will receive an upfront payment and research funding, and will be eligible to receive additional development and sales milestone payments based on the exclusivity of targets selected by Takeda.
Luc Boblet, co-founder and CEO of Egle Tx, commented “We are thrilled to engage with Takeda to fully exploit the great therapeutic potential of inhibiting the most immunosuppressive arm of immunity to restore antitumor immune response. We believe that joining forces would be the most efficient path to successfully develop novel generation of anti-Treg immunotherapies for the benefit of patients.”
“Working with Egle to leverage the unique translational derived patient data bringing tumor-specific Treg targets is an exciting prospect to further advance our immuno-oncology drug discovery efforts,” said Loïc Vincent, Head, Oncology Drug Discovery Unit at Takeda. “Targeting tumor-infiltrating regulatory T-cells to overcome the immune suppression in tumor microenvironments will complement our current immuno-oncology approaches and help advance an exciting portfolio.”
In addition to the funding of the multi-target research collaboration, Takeda will invest €4.6 million in convertible debt through its venture arm, Takeda Ventures, Inc. (“TVI”), to support Egle’s corporate growth and internal programs on IL-2-based Treg modulation. Egle’s flagship program pioneers the dis-engagement of tumor-infiltrating Treg through unique proprietary series of IL-2 variants that act as IL-2 antagonists.
“While the whole competition converges solely on a similar approach to enhance effector T cells by disrupting binding of IL-2 to Tregs, our IL-2 variants conserve intact IL-2 binding to CD25, conferring a unique mechanism of action for starving Treg from endogenous IL-2, while leaving active the CD8+ effector T cell arm of the immune response,” Luc Boblet added. “Takeda’s equity commitment will help Egle’s launch strikingly hit the road building on our excellent scientific foundation.”
About Egle Therapeutics
Established in early 2020, as a spin-out of Institut Curie by Luc Boblet, serial biotech entrepreneur (former co-founder and CEO of PathoQuest, and former co-founder and CEO of H-Immune sold to HifiBio Therapeutics) and Dr Eliane Piaggio, PhD, renowned immunologist in the Treg / IL-2 field (INSERM Research Director, Head of the Translational Immunotherapy Team – TransImm – at Institut Curie), Egle Therapeutics is developing first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases.
The key element of Egle’s core approach is the leveraging of its translational-based target discovery engine to unveil novel therapeutic Treg targets and vectorize computationally designed resurfaced cytokines acting as antagonists or as selective Treg-agonists. Egle’s flagship program pioneers dis-engagement of tumor-infiltrating Tregs through a proprietary series of IL-2 variants featuring a unique antagonism mechanism of action.
To find out more about Egle Therapeutics, please visit www.egle-tx.com
Contact
Luc Boblet
Chief Executive Officer
Email: lboblet@egle-tx.com
TAGS:Treg Modulating egle Cells
<<< Thank you for your visit >>>
Websites to related : Gärtnerei Strillinger | STRILLI
STRILLINGER Gemüse und Blumen Gärtnerei in Kufstein TIROL Menü
Niederhuber & Partner RechtsanwEiendomsmegler Notar | Salgsgara
Netregister X |
Navigation KezdőlapDokumentummenedzsmentFelhasználási terül
Treffen Sie unsere Escort LadiesEnglishHomeESCORT LADIESInfosAbout UsPrivate ApartmentData ProtectionCity GuideLocationsAargauBaselBernBodenseeChurGlarusGraubündenInterlakenLaus
HERZ d.d. – Stanica za tehSkip to main content Menu O NAMAAUTOŠKOLA HERZ – JAGUARAUTOŠKOLA HERZ – JAGUARO namaInstruktoriVozni parkPrometno vježbalištePrigo
Studienbegleitung für TheologieTogglenavigation Unsere Termine
Fiscalité Assurance Vie - les rLes règles de la fiscalité d'une assurance vieAlors que vous vous préparez pour une autre saison fiscale, assurez-vous de regarder votre assurance-
Economic Development Division |:root{--color_0:255,255,255;--color_27:153,153,153;--color_1:255,255,255;--color_2:0,0,0;--color_3:237,28,36;--color_4:0,136,203;--col
HOME | custom-cells:root{--color_0:255,255,255;--color_27:233,159,134;--color_1:255,255,255;--color_2:0,0,0;--color_3:237,28,36;--color_4:0,136,203;--col
adsHot Websites